Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis

Therapeutic Advances in Endocrinology and Metabolism

Volumn 5, Issue 2, 2014, Pages 34-38

  Al Badri, Marwa R ^a   Azar, Sami T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

dipeptidyl peptidase 4 inhibitors; glucagon like peptide 1; glycemic control; incretin; liraglutide; metabolic syndrome; obesity; psoriasis; type 2 diabetes

Indexed keywords

ADALIMUMAB; DIPEPTIDYL PEPTIDASE IV; ETRETIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; INTERLEUKIN 17; INTERLEUKIN 7; LIRAGLUTIDE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; SITAGLIPTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; GAMMA DELTA T LYMPHOCYTE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; NATURAL KILLER CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN CELL;

EID: 84906350421     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018814543483     Document Type: Review

References (11)

1. Ahern T. Tobin A. Corrigan M. Hogan A. Sweeney C. Kirby B. et al. (2013) Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: A prospective cohort study. J Eur Acad Dermatol Venereol 27: 1440–1443.
2. Buysschaert M. Tennstedt D. Preumont V. (2012) Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab 38: 86–88.
3. Drucker D. Rosen C. (2011) Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 54: 2741-2744.
4. Faurschou A. Knop F. Thyssen J. Zachariae C. Skov L. Vilsbøll T. (2014) Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol 51: 147–150.
5. Faurschou A. Pedersen J. Gyldenløve M. Poulsen S. Holst J. Thyssen J. et al. (2013) Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol 22: 150–152.
6. Faurschou A. Zachariae C. Skov L. Vilsbøll T. Knop F. (2011) Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism? Med Hypotheses 77: 1098–1101.
7. Hogan A. Tobin A. Ahern T. Corrigan M. Gaoatswe G. Jackson R. et al. (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54: 2745–2754.
8. Nishioka T. Shinohara M. Tanimoto N. Kumagai C. Hashimoto K. (2012) Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology 224: 20–21.
9. Raychaudhuri S. Maverakis E. Raychaudhuri S. (2014) Diagnosis and classification of psoriasis. Autoimmun Rev 13: 490–495.
10. Reid C. Tobin A. Ahern T. O'Shea D. Kirby B. (2013) Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br J Dermatol 169: 230–231.
11. Schön M. Boehncke W. (2005) Psoriasis. N Engl J Med 352: 1899-1912.